We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On July 23, according to latest announcement in the official website of the National Medical Products Administration (NMPA), the recombinant coagulation factor VIII (SCT800) for injection developed by Shenzhou Cell Biotechnology.